# 内源性大麻素治疗市场

> 大麻素治疗市场研究报告按产品类型（基于大麻素的药物、基于大麻素的补充剂、基于大麻素的外用药）、按应用（疼痛管理、神经系统疾病、心理健康疾病、癌症症状管理）、按给药途径（口服、外用、吸入、经皮）、按最终用户（医院、诊所、居家护理）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 24.71%
- **2024:** $ 6.4 Billion
- **2025:** $ 7.98 Billion
- **2035:** $ 72.65 Billion
- **Key Players:** GW Pharmaceuticals (GB), Canopy Growth Corporation (CA), Aurora Cannabis (CA), Tilray, Inc. (CA), Cronos Group (CA), Aphria Inc. (CA), Zynerba Pharmaceuticals (US), Epidiolex (US), Cura Cannabis Solutions (US)

**Report ID:** MRFR/HC/38243-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/endocannabinoid-therapeutics-market-40270

---

## Market Summary

## **Endocannabinoid Therapeutics Market Overview**

As per MRFR analysis, the Endocannabinoid Therapeutics Market Size was estimated at 6.40 (USD Billion) in 2024. The Endocannabinoid Therapeutics Market Industry is expected to grow from 7.98 (USD Billion) in 2025 to 58.25 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 24.71% during the forecast period (2025 - 2034).

### **Key Endocannabinoid Therapeutics Market Trends Highlighted**

The Endocannabinoid Therapeutics Market is experiencing significant growth driven by increasing awareness of the therapeutic potential of cannabinoids in treating various medical conditions. Key market drivers include the rising prevalence of chronic diseases, growing acceptance of cannabis-based treatments, and ongoing research into the benefits of cannabinoids. This acceptance is further bolstered by legislative changes in several regions, paving the way for more comprehensive clinical studies and eventual market expansion. There are ample opportunities to be explored in various sectors, such as mental health treatment, pain management, and neurological disorders.

Novel methods of delivery of cannabinoids, including edibles, topicals and vaporizers, are also creating an increased interest and accessibility to such therapies. Furthermore, synthetic cannabinoids and cannabinoid-containing pharmaceuticals are quite effective in meeting many medical needs of patients with serious illnesses and, thereby, improving their quality of care. Recent trends have revealed an increased investment and partnership interest among pharmaceutical and research entities focusing on the cannabinoid space. There is also a growing trend towards personalized medicine, which advocates for the targeting of the therapy to the specific patient through cannabinoids.

As more and more states and countries start to allow cannabis and more people start to warm towards cannabis, it is possible that the competitive landscape will change even more. In the general context, the Endocannabinoid Therapeutics Market has the potential for faster growth, with the key drivers being the shift in paradigm and growth in science that is instigating attitudinal changes toward cannabinoid-derived therapies.

Endocannabinoid Therapeutics Market

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Endocannabinoid Therapeutics Market Drivers**

### **Increasing Acceptance of Cannabinoid-based Products**

The growing acceptance of cannabinoid-based products among healthcare professionals and patients is one of the most significant drivers of the Endocannabinoid Therapeutics Market industry. As research continues to validate the therapeutic benefits of cannabinoids in treating various conditions, including chronic pain, epilepsy, and anxiety, more patients and doctors are turning towards these natural alternatives instead of conventional pharmacological treatments.This shift is reflected in emerging legislation and regulatory changes that accommodate the use of medical marijuana and cannabinoid-derived therapies. The expansion of this market is further fueled by increased awareness and education about the benefits and risks associated with cannabinoid therapies.

With a growing number of patients seeking alternative treatments, the demand for innovative and effective cannabinoid-based therapeutic solutions is expected to rise sharply.

As the stigma surrounding cannabis diminishes, healthcare providers are more likely to incorporate these treatments into their practice, thereby expanding market accessibility and fostering significant growth. Furthermore, the evolution of new formulations and delivery methods, such as edibles, tinctures, and transdermal patches, is likely to enhance patient compliance and satisfaction. The overall societal attitudinal shift towards the use of cannabinoids for health benefits dramatically contributes to the escalating acceptance of these treatments, igniting potential investment and development in the Endocannabinoid Therapeutics Market industry.

### **Growing Research and Development Activities**

The commitment to research and development in the field of cannabinoid therapies is a pivotal driving force within the Endocannabinoid Therapeutics Market industry. With increasing investments by pharmaceutical firms and research institutions, the exploration of cannabinoids' efficacy and safety for a broader range of medical conditions is expanding. A robust pipeline of clinical trials aimed at assessing the therapeutic possibilities of cannabinoids illustrates the industry's dedication to innovation.As more positive results emerge, these advancements are likely to encourage regulatory approval and market entry of new cannabinoid-based medications, thereby propelling industry growth.

### **Expanding Legalization of Cannabis for Medical Use**

The ongoing legalization of cannabis for medicinal uses across various regions significantly boosts the Endocannabinoid Therapeutics Market industry. Governments are increasingly recognizing the therapeutic potential of cannabinoids, leading to legislative changes that allow for the cultivation, distribution, and consumption of medical cannabis. This trend not only broadens the market horizon by introducing new players into the field but also enhances research opportunities, as legal frameworks encourage scientific inquiry into the potential medical benefits of cannabinoids.As more jurisdictions implement favorable policies, accessibility to cannabinoid-based treatments is set to improve, ultimately driving market expansion.

## **Endocannabinoid Therapeutics Market Segment Insights**

### **Endocannabinoid Therapeutics Market Product Type Insights**

The Endocannabinoid Therapeutics Market has been increasingly focusing on various product types which include Cannabinoid-based Medications, Cannabinoid-based Supplements, and Cannabinoid-based Topicals. In 2023, the overall market was valued at 4.11 USD Billion, showcasing significant growth potential as it is projected to reach 30.0 USD Billion by 2032, reflecting an expanding interest in therapeutic applications of cannabinoids.

Among the different product types, Cannabinoid-based Medications held a majority share, valued at 2.11 USD Billion in 2023 and expected to expand to 14.5 USD Billion by 2032.This sub-segment is particularly crucial as these medications are often backed by research and clinical trials, primarily aimed at treating a variety of health issues, including chronic pain, anxiety, and epilepsy, which drives their significant market presence. Moreover, Cannabinoid-based Supplements were valued at 1.47 USD Billion in 2023 and are expected to grow to 10.5 USD Billion by 2032.

This segment is gaining traction as consumers increasingly seek natural alternatives for wellness and health, making it essential in the overall market landscape.Lastly, Cannabinoid-based Topicals, though comparatively smaller, valued at 0.53 USD Billion in 2023 and projected to reach 5.0 USD Billion by 2032, cater to skincare and localized treatment needs, thus serving a niche but important segment in the market. The diversity in product types reflects broader market trends, where advancements in research and development are facilitating the exploration of cannabinoids across various therapeutic domains.

The growth drivers for this market are attributed to an increasing acceptance of cannabis-derived products, rising awareness of health benefits, and a growing demand for natural treatments.

However, challenges such as regulatory hurdles and varying legal statuses across regions pose hurdles that market players must navigate. The Endocannabinoid Therapeutics Market data emphasize a robust segmentation that highlights the importance of understanding consumer preferences and market dynamics, ensuring that companies can effectively position their products and leverage growth opportunities while being mindful of the challenges ahead. The overall statistics reveal an industry that is evolving rapidly, demonstrating strong potential for substantial growth across all product types in the upcoming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Endocannabinoid Therapeutics Market Application Insights**

In 2023, the Endocannabinoid Therapeutics Market is expected to be valued at 4.11 billion USD, highlighting significant opportunities within the Application segment. This market has showcased robust growth, driven by increasing demand for natural and effective therapeutic solutions. Within this segment, various applications, including Pain Management, Neurological Disorders, Mental Health Disorders, and Cancer Symptom Management, have emerged as critical areas. Pain Management holds a considerable share of the market, reflecting the growing awareness of cannabinoid-based therapies among patients looking for alternatives to conventional pain relief.

Neurological Disorders also represent a vital focus due to the compelling evidence supporting cannabinoids in treating conditions like epilepsy and multiple sclerosis.

Additionally, the Mental Health Disorders category is evolving, as research indicates the potential benefits of cannabis compounds in alleviating symptoms of anxiety and depression. Cancer Symptom Management is another prominent area where cannabinoids can provide relief from pain, nausea, and appetite loss in patients undergoing treatment. The Endocannabinoid Therapeutics Market revenue is influenced by these diverse applications, illustrating the industry's potential for growth and expansion.The market growth is fueled by the increasing legalization of cannabis, ongoing research, and supportive regulations, although challenges such as regulatory hurdles and public misconceptions continue to persist.

### **Endocannabinoid Therapeutics Market Route of Administration Insights**

The Endocannabinoid Therapeutics Market is expected to see substantial growth, particularly in the Route of Administration segment. In 2023, the overall market was valued at 4.11 billion USD, reflecting a growing recognition of endocannabinoid treatments. The increasing preference for oral administration underscores its convenience and effectiveness, leading to a significant share in market demand. Furthermore, topical applications are gaining prominence due to their localized therapeutic effects, making them an appealing choice for patients seeking targeted treatment.Inhalation methods are also notable for their rapid onset of effects, appealing to patients requiring quick relief.

Lastly, transdermal administration combines the advantages of systemic delivery with patient compliance, contributing to its importance in the market landscape. The significant diversity in available routes of administration provides opportunities for innovation and expanding patient access, fueling further market growth as healthcare professionals continue to explore their benefits across various therapeutic areas. The Endocannabinoid Therapeutics Market data indicates a robust environment driven by these dynamic and influential administration methods.

### **Endocannabinoid Therapeutics Market End User Insights**

The Endocannabinoid Therapeutics Market, with a revenue of 4.11 billion USD in 2023, exhibits significant potential for growth, particularly in the End User segment. Among the notable participants in this market are hospitals, clinics, and homecare settings, each contributing uniquely to the industry's expansion. Hospitals typically dominate this segment due to their comprehensive facilities and expert healthcare providers, offering a range of therapies that include endocannabinoid treatments. Clinics also play a significant role in providing specialized care and accessibility for patients seeking alternative therapies.

Meanwhile, homecare has emerged as a crucial trend, reflecting the growing demand for patient-centered treatment options that offer convenience and comfort. This shift towards homecare underscores the opportunity for innovative therapeutic solutions that cater to individual patient needs, fostering enhanced patient outcomes. As the Endocannabinoid Therapeutics Market data suggests a staggering growth potential, understanding these key End User trends is essential for stakeholders aiming to navigate this evolving landscape effectively. Overall, the Endocannabinoid Therapeutics Market segmentation reveals a landscape rich with opportunities and challenges, driven by the increasing acceptance of endocannabinoid therapies across various healthcare settings.

### **Endocannabinoid Therapeutics Market Regional Insights**

The Endocannabinoid Therapeutics Market exhibits a robust structure across various regions, with significant valuations in 2023. North America commands a substantial portion, valued at 2.0 USD Billion, and is projected to dominate the market by reaching 15.0 USD Billion by 2032, reflecting its majority holding in the overall industry. Europe follows with a notable valuation of 1.0 USD Billion in 2023, set to increase to 7.5 USD Billion, highlighting its significant role in the Endocannabinoid Therapeutics Market.

In the Asia-Pacific (APAC) region, the market reached 0.8 USD Billion in 2023 and is expected to grow to 5.0 USD Billion, showcasing emerging opportunities driven by increasing acceptance and demand. South America, though smaller, valued at 0.2 USD Billion in 2023, is anticipated to see growth to 1.0 USD Billion, reflecting growing interest in therapeutic applications. The Middle East and Africa (MEA) represent the least dominant sector with a current value of 0.11 USD Billion, expected to grow to 1.5 USD Billion, illustrating emerging potential.

The varying valuations across these regions denote unique market dynamics influenced by regulatory frameworks, consumer acceptance, and healthcare trends influencing market growth.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Endocannabinoid Therapeutics Market Key Players and Competitive Insights**

The Endocannabinoid Therapeutics Market has emerged as a dynamic and rapidly evolving sector within the broader pharmacological landscape. Driven by increasing legalizations and shifting societal perceptions regarding cannabis, the market is characterized by a range of players vying for dominance and market share. Companies involved in this sector are focused on the development of innovative products that harness the therapeutic potential of cannabinoids. This includes extensive research and development efforts aimed at both new formulations and the enhancement of existing products to ensure compliance with regulatory frameworks.

The competition is fueled by advancements in cultivation techniques and extraction processes, with firms investing substantial resources to understand the endocannabinoid system and its implications for various health conditions.

As more players enter the market and new products are developed, the competitive landscape continues to shift, making it essential for companies to establish a strong presence and differentiated offerings.Curaleaf Holdings Inc. has positioned itself as a leader in the Endocannabinoid Therapeutics Market, leveraging its vast operational scale and extensive product portfolio. With a commitment to high-quality cannabinoid-based therapeutics, the company has invested significantly in research and development to create effective and safe products tailored to various therapeutic needs. Curaleaf's strengths lie in its ability to navigate complex regulatory environments while maintaining a strong brand identity within the cannabis space.

The company's strategic partnerships and robust distribution networks further enhance its market presence, allowing for effective penetration in diverse geographical locations. With a keen focus on innovation and consumer education, Curaleaf is well-positioned to capitalize on the growing demand for cannabinoid therapeutics, demonstrating its commitment to improving patient outcomes and advancing the industry.

Cresco Labs Inc has emerged as a key player in the Endocannabinoid Therapeutics Market, distinguished by its focus on high-quality cannabis products and a strong commitment to responsible growth. Known for its cultivation and manufacturing expertise, Cresco Labs has established a solid reputation within the industry by producing a diverse range of cannabinoid-based therapies. The company's strengths are highlighted by its operational excellence, which allows it to deliver consistent product quality and reliability, a crucial factor within the therapeutic domain. Cresco Labs emphasizes innovation in product development, consistently integrating consumer feedback to enhance and adapt its offerings.

The company’s wide-ranging distribution channels also contribute to its success, ensuring that its products are accessible to a broad audience. With a strategic vision geared towards sustainability and long-term growth, Cresco Labs is poised to make significant contributions to the development of cannabinoid therapeutics while effectively addressing the evolving needs of consumers.

### **Key Companies in the Endocannabinoid Therapeutics Market Include**

- Curaleaf Holdings Inc
- Cresco Labs Inc
- Planet 13 Holdings Inc
- Aurora Cannabis Inc
- Ascend Wellness Holdings Inc
- GW Pharmaceuticals plc
- Trulieve Cannabis Corp
- [**Tilray Inc**](https://ir.tilray.com/node/6696/html)
- Green Thumb Industries Inc
- Harvest Health and Recreation Inc
- Verano Holdings Corp
- Cronos Group Inc
- MedMen Enterprises Inc
- Canopy Growth Corporation
- Aphria Inc

## **Endocannabinoid Therapeutics Market Industry Developments**

Recent developments in the Endocannabinoid Therapeutics Market have seen companies like Curaleaf Holdings Inc. and Cresco Labs Inc. expanding their operations through strategic partnerships and product launches aimed at enhancing their market presence. The increasing acceptance of cannabis-based therapies, particularly in the treatment of chronic pain and neurological disorders, continues to drive demand. Meanwhile, Planet 13 Holdings Inc. has reported significant revenue growth due to its innovative retail strategies, while Aurora Cannabis Inc. has focused on enhancing its research capabilities to support product development.

Ascend Wellness Holdings Inc. has been actively expanding its footprint in the U.S. market, recognizing the potential for growth amid changing regulations. Notably, GW Pharmaceuticals plc recently made headlines after the acquisition of new research facilities, reinforcing its commitment to advancing cannabinoid-based medicines. Mergers and acquisitions within the sector are also noteworthy, with Trulieve Cannabis Corp and Tilray Inc engaging in transactions that aim to consolidate their market positions.

The overall market valuation of companies such as Green Thumb Industries Inc. and Harvest Health and Recreation Inc. has seen measurable increases, reflecting growing investor confidence and the potential for continued expansion in the sector.

## **Endocannabinoid Therapeutics Market Segmentation Insights**

### **Endocannabinoid Therapeutics Market Product Type Outlook**

- Cannabinoid-based Medications
- Cannabinoid-based Supplements
- Cannabinoid-based Topicals

### **Endocannabinoid Therapeutics Market Application Outlook**

- Pain Management
- Neurological Disorders
- Mental Health Disorders
- Cancer Symptom Management

### **Endocannabinoid Therapeutics Market Route of Administration Outlook**

- Oral
- Topical
- Inhalation
- Transdermal

### **Endocannabinoid Therapeutics Market End User Outlook**

- Hospitals
- Clinics
- Homecare

### **Endocannabinoid Therapeutics Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 交付系统的创新

大麻素疗法的递送系统的进步有望提高内源性大麻素治疗市场中产品的疗效和吸引力。正在开发创新配方，如透皮贴片、吸入器和舌下喷雾，以改善生物利用度和患者依从性。这些新颖的递送方法可能允许更精确的剂量和更快的效果出现，从而解决一些与传统消费方法相关的局限性。随着这些创新的普及，它们可能吸引更广泛的消费者，从而扩大市场。内源性大麻素治疗市场将从这些技术进步中受益，这可能导致销售和市场渗透的增加。

### 慢性疾病的日益普遍

慢性疾病如关节炎、多发性硬化症和癫痫的发病率上升似乎是内源性大麻素治疗市场的重要驱动因素。随着这些疾病的日益普遍，对有效治疗方案的需求也在加剧。研究表明，大麻素可能为这些疾病相关症状提供缓解，从而引发对其治疗潜力的日益关注。事实上，研究显示，仅在美国就有大约5000万成年人遭受慢性疼痛，这可能通过基于大麻素的疗法得到缓解。这一趋势表明，随着医疗服务提供者越来越多地考虑大麻素疗法作为可行的治疗替代方案，内源性大麻素治疗市场可能会扩展。

### 对大麻研究的投资增加

对大麻研究和开发的投资不断增加，预计将对内源性大麻素治疗市场产生重大影响。公共和私营部门都在分配大量资源，以探索大麻素的治疗应用，导致临床试验和科学研究的激增。这一资金的涌入可能加速新型基于大麻素的治疗的发现，可能解决多种医疗状况。随着研究继续验证这些疗法的有效性，内源性大麻素治疗市场可能会经历显著增长，推动这一市场的是一系列满足患者不断变化需求的创新产品。

### 消费者意识和接受度的提高

消费者对大麻素治疗益处的认识正在上升，这可能会显著影响内源性大麻素治疗市场。随着教育倡议和宣传活动的增加，越来越多的人开始了解大麻治疗的潜在健康益处。调查显示，人口中有相当大比例的人愿意使用大麻衍生产品用于医疗目的。这种观念的转变可能会推动对大麻素治疗的需求，因为患者寻求传统药物的替代品。因此，随着接受度在各个群体中不断扩大，内源性大麻素治疗市场可能会经历强劲增长。

### 监管支持与不断发展的立法

围绕大麻素疗法的不断变化的监管环境可能在塑造内源性大麻素治疗市场中发挥关键作用。随着各国政府和监管机构开始认识到大麻素的治疗潜力，建立明确的使用指南和框架的趋势日益增长。这种监管支持可能促进研究和开发工作，鼓励制药公司投资于基于大麻素的产品。此外，随着立法变得更加有利，市场可能会迎来新进入者和创新疗法的涌入，最终增强内源性大麻素治疗市场的竞争和消费者选择。

## Future Outlook

大麻素治疗市场预计将在2024年至2035年间以24.71%的年复合增长率增长，推动因素包括法律化进程的加快、消费者意识的提高以及研究的进展。

**New opportunities:**

- 针对慢性疼痛管理的个性化大麻素疗法的开发。

到2035年，市场预计将强劲，反映出显著的增长和创新。

## Segment Insights

### 按类型：基于大麻素的药物（最大）与基于大麻素的补充剂（增长最快）

内源性大麻素治疗市场展示了一个多样化的格局，主要由三个部分组成：基于大麻素的药物、基于大麻素的补充剂和基于大麻素的外用产品。基于大麻素的药物在这个市场中占据最大的份额，推动因素是对大麻素在治疗应用中日益增加的接受度和认可度。相比之下，基于大麻素的补充剂正在迅速增长，吸引了对自然和整体健康方法感兴趣的健康意识人群，成为市场中的重要参与者。
这些细分市场的增长轨迹受到多个因素的影响，包括慢性疾病的日益普遍、患者意识的提高以及支持大麻素药用益处的临床研究的扩展。值得注意的是，基于大麻素的补充剂在寻求各种健康状况替代疗法的消费者中越来越受欢迎，从而调整了内源性大麻素治疗市场的整体动态，并促使制造商创新以满足日益增长的需求。

基于大麻素的药物（主流）与基于大麻素的外用药（新兴）

基于大麻素的药物目前在内源性大麻素治疗市场中占据主导地位，主要是由于它们在治疗慢性疼痛、癫痫和与炎症相关的疾病等严重健康状况方面的确立疗效。它们受益于强有力的监管框架，这使得它们在临床环境中的广泛可用性和应用成为可能。相反，基于大麻素的外用药物正在成为一种受欢迎的替代选择，特别是对于寻求局部缓解而不产生全身性影响的消费者。这个细分市场正在获得关注，尤其是在护肤和健康市场，消费者越来越倾向于选择自然解决方案。这两个细分市场的对比展示了市场内更广泛的趋势，即消费者对基于大麻素的解决方案的认知和偏好正在迅速发展。

### 按应用：疼痛管理（最大）与神经系统疾病（增长最快）

大麻素治疗市场在其应用领域中正经历着明显的动态变化，其中疼痛管理在市场份额中占据领先地位。该领域因其在解决慢性疼痛状况方面的有效性而广受认可，推动了巨大的需求。神经系统疾病虽然市场份额较小，但随着对内源性大麻素系统及其在癫痫和多发性硬化等疾病中的作用理解的加深，展现出快速增长的趋势，吸引了对治疗应用的更多关注。
增长趋势分析显示，疼痛管理因其确立的治疗益处和在医疗提供者及患者中的广泛接受度，仍然是主导应用。相反，神经系统疾病正在获得动力，受到日益增加的研究和临床试验的推动。神经系统疾病的发病率上升以及支持性的监管环境催化了该领域的增长，使其成为一个重要的投资和创新领域。

疼痛管理（主导）与癌症症状管理（新兴）

疼痛管理已被确立为内源性大麻素治疗市场的主导应用。该细分市场受益于大量临床证据，支持大麻素在缓解各种疼痛形式方面的有效性。它在医疗从业者和患者中广泛接受，使其在竞争中处于有利地位。另一方面，癌症症状管理作为一种重要应用正在崛起，吸引寻求缓解治疗引起的症状（如恶心和食欲缺乏）的患者。该细分市场的增长得益于对大麻素在改善癌症患者生活质量方面有效性的日益研究，突显了在肿瘤护理中整合治疗方法的必要性。

### 按给药途径：口服（最大）与吸入（增长最快）

在内源性大麻素治疗市场中，给药途径细分展示了多样化的格局，口服给药占据了最大的市场份额。这种方法因其便利性和易用性而获得了显著的关注，特别是对于寻求治疗效果的患者。紧随其后的是经皮给药，这一方法也开辟了相当可观的市场，特别吸引那些希望获得局部效果的患者。相比之下，吸入法虽然目前在市场份额上较小，但由于其快速起效和有效性，正在迅速流行，表明消费者偏好的动态变化。
这一细分市场的增长趋势受到消费者对大麻衍生产品接受度不断提高以及配方技术进步的推动。吸入法的兴起表明了对治疗效果即时性的强烈追求，迎合了寻求快速缓解的个体需求。同时，口服途径的持续主导地位强调了治疗范式的基础性转变，拥抱与以患者为中心的护理相协调的自然替代品。这一不断演变的格局正在塑造内源性大麻素治疗市场的未来，使其适应不断变化的患者需求和监管环境。

口服（主导）与吸入（新兴）

口服途径是内源性大麻素治疗市场的主要给药方式。由于其用户友好性，患者可以轻松地消费如油和胶囊等大麻素产品，因此受到青睐。这种方法提供了大麻素在体内的稳定释放，带来渐进和持续的治疗效果，这对于慢性病尤其具有吸引力。另一方面，吸入技术，包括蒸发和吸烟，代表了一种新兴的方法，因其快速吸收和高效性而逐渐受到重视。经常被寻求即时缓解的患者所偏好，吸入方法在年轻人群中越来越受欢迎，他们更重视快速的治疗反应。这两个细分市场的对比特征突显了患者的多样化偏好，并强调了市场的复杂性。

### 按最终用户：医院（最大）与诊所（增长最快）

在内源性大麻素治疗市场中，终端用户之间的市场份额分布显示，医院占据了最大的份额，受益于其综合医疗服务，结合了先进的治疗方法。虽然诊所的当前市场份额较小，但由于越来越多地采用针对门诊护理的基于大麻素的治疗，正在成为一个关键的细分市场。这种治疗方向的转变支持了诊所中个性化医疗的上升趋势，以管理慢性疼痛和焦虑等疾病。

医院：主导与诊所：新兴

医院作为内源性大麻素治疗市场的主要终端用户，具备提供多元化治疗方案的能力，并拥有广泛的患者管理基础设施。它们通常将这些疗法整合到疼痛管理和姑息治疗的方案中。在新兴方面，诊所通过提供专业的大麻素疗法来开辟自己的市场，满足偏好门诊环境的患者。这一增长得益于患者对医疗大麻的认识和接受度的提高，以及有利的监管变化。诊所正成为寻求有效替代传统药物的患者的重要接入点。

## Regional Market Share Analysis

### 北美：创新的领先市场

北美是内源性大麻素治疗的最大市场，约占全球市场份额的60%。该地区的增长受到对医疗用途大麻接受度提高、支持性监管框架以及消费者对替代疗法需求上升的推动。美国在这一市场中处于领先地位，其次是加拿大，后者约占整体市场的20%。各州大麻合法化等监管催化剂进一步增强了市场动态。北美的竞争格局强劲，主要参与者包括GW制药、Canopy Growth Corporation和Tilray, Inc.。成熟企业和创新初创公司的存在为研究和开发创造了动态环境。美国市场的产品种类繁多，包括油、胶囊和食品，满足不同消费者的需求。这种竞争优势使北美在内源性大麻素治疗领域处于领先地位。

### 欧洲：具有潜力的新兴市场

欧洲正在迅速崛起为内源性大麻素治疗市场的重要参与者，目前约占全球市场份额的25%。增长受到各国医疗大麻合法化进程加快以及对其治疗益处认识提高的推动。德国和英国是欧洲最大的市场，分别贡献约10%和8%。监管框架正在演变，各国政府积极支持该领域的研究和开发。欧洲的领先国家包括德国、英国和意大利，竞争格局包括成熟的制药公司和新进入者。像Aurora Cannabis和Tilray这样的主要参与者增强了市场动态。欧洲市场的特点是对大麻基药物的需求不断增长，重点关注以患者为中心的解决方案。预计这一趋势将推动该地区进一步投资和创新。

### 亚太地区：大麻的新兴强国

亚太地区在内源性大麻素治疗市场中正崛起为一股新兴力量，目前约占全球市场份额的10%。该地区的增长受到对医疗用途大麻兴趣增加的推动，特别是在澳大利亚和新西兰等国，相关法规变得更加有利。对替代疗法的需求上升，各国政府开始认识到大麻基治疗的潜在益处，这预计将催化市场扩张。亚太地区的主要参与者包括本地公司和希望进入这一新兴市场的国际公司。澳大利亚凭借其进步的监管框架走在前列，而日本和韩国等国也在探索医疗用途的大麻。竞争格局正在演变，重点是研究和开发，以创造适应地区需求的创新治疗解决方案。这使亚太地区成为内源性大麻素治疗未来增长的有希望市场。

### 中东和非洲：未开发的市场机会

中东和非洲地区目前是内源性大麻素治疗的未开发市场，约占全球市场份额的5%。增长潜力巨大，受到对医疗应用大麻兴趣增加和监管环境演变的推动。南非等国在合法化努力中走在前列，这可能为更广泛的接受和市场增长铺平道路。该地区多样化的医疗需求为大麻基治疗提供了独特的机会。该地区的领先国家包括南非和以色列，以其对医疗大麻的进步立场而闻名。竞争格局仍在发展中，混合了本地初创公司和探索机会的国际公司。随着法规的不断演变，市场预计将吸引投资和创新，使中东和非洲成为内源性大麻素治疗市场的未来参与者。

## Competitive Benchmarking

内源性大麻素治疗市场目前的特点是动态的竞争格局，受到消费者对基于大麻素的疗法需求增加和支持其疗效的研究不断增加的推动。GW制药（GB）、Canopy Growth Corporation（CA）和Tilray, Inc.（CA）等主要参与者通过创新和合作伙伴关系战略性地定位自己。GW制药（GB）专注于扩大其产品组合，特别是在癫痫治疗领域，而Canopy Growth Corporation（CA）则在研发方面进行了大量投资，以增强其治疗产品。Tilray, Inc.（CA）也在追求战略合作，以扩大其市场覆盖，表明在塑造竞争环境方面，创新和战略合作的共同重视。

在商业策略方面，各公司越来越多地本地化制造和优化供应链，以提高效率并降低成本。内源性大麻素治疗市场似乎适度分散，多个参与者争夺市场份额。这些主要参与者的集体影响力显著，因为他们不仅推动创新，还设定行业标准，较小的公司可能会遵循这些标准，从而影响整体市场结构。

在2025年8月，GW制药（GB）宣布与一家领先的研究机构合作，开发用于慢性疼痛管理的新型基于大麻素的疗法。这一战略举措强调了公司扩大其治疗应用和增强其在快速发展的市场中竞争优势的承诺。通过利用学术专业知识，GW制药（GB）旨在加速创新治疗的开发，可能使其在疼痛管理解决方案中占据领导地位。

在2025年9月，Canopy Growth Corporation（CA）推出了一系列针对健康领域的基于大麻素的产品，目标是寻求自然替代健康管理的消费者。这一举措反映了Canopy多样化产品组合的战略，并利用日益流行的健康趋势，越来越受到注重健康的消费者的欢迎。此次发布不仅增强了Canopy的市场存在感，还与消费者对整体健康解决方案的更广泛偏好相一致。

在2025年10月，Tilray, Inc.（CA）完成了对一家专注于大麻素研究的小型生物技术公司的收购，这预计将显著增强其研发能力。这一收购表明了Tilray的激进增长战略及其专注于增强产品管道。通过整合专业知识和技术，Tilray旨在加速创新疗法的开发，从而增强其在市场中的竞争地位。

截至2025年10月，内源性大麻素治疗市场的当前趋势包括向数字化、可持续性和人工智能在研发过程中的整合的明显转变。战略联盟越来越多地塑造竞争格局，因为公司认识到合作在推动创新中的价值。展望未来，竞争差异化可能会从传统的基于价格的竞争演变为关注技术进步、创新产品开发和可靠的供应链管理，这表明市场环境将更加复杂和韧性。

## Recent News & Developments

在内源性大麻素治疗市场的最新发展中，Curaleaf Holdings Inc. 和 Cresco Labs Inc. 通过战略合作伙伴关系和产品发布扩大了其业务，旨在增强市场存在感。对基于大麻的疗法的接受度不断提高，特别是在慢性疼痛和神经系统疾病的治疗中，持续推动需求。同时，Planet 13 Holdings Inc. 报告称，由于其创新的零售策略，收入显著增长，而Aurora Cannabis Inc. 则专注于增强其研究能力，以支持产品开发。

Ascend Wellness Holdings Inc. 正在积极扩大其在美国市场的足迹，认识到在法规变化中增长的潜力。值得注意的是，GW Pharmaceuticals plc 最近因收购新研究设施而成为头条新闻，进一步巩固了其推进大麻素药物的承诺。该行业内的并购活动也颇为引人注目，Trulieve Cannabis Corp 和 Tilray Inc. 进行的交易旨在巩固其市场地位。

如Green Thumb Industries Inc. 和 Harvest Health and Recreation Inc. 等公司的整体市场估值已显著增加，反映出投资者信心的增强以及该行业持续扩张的潜力。

## Report Scope

| 2024年市场规模 | 6.401（十亿美元） |
| --- | --- |
| 2025年市场规模 | 7.983（十亿美元） |
| 2035年市场规模 | 72.65（十亿美元） |
| 复合年增长率（CAGR） | 24.71%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 对大麻素受体的新兴研究表明在内源性大麻素治疗市场中具有新型治疗应用的潜力。 |
| 主要市场动态 | 消费者对天然疗法的需求上升推动了内源性大麻素治疗市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 内源性大麻素治疗市场的当前估值是多少？**
A: 2024年，内源性大麻素治疗市场的估值为64.01亿美元。

**Q: 到2035年，内源性大麻素治疗市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到726.5亿美元。

**Q: 在2025年至2035年的预测期内，内源性大麻素治疗市场的预期CAGR是多少？**
A: 2025年至2035年期间，市场的预期CAGR为24.71%。

**Q: 2024年，哪一部分的内源性大麻素治疗市场估值最高？**
A: 在2024年，基于大麻素的药物细分市场的估值最高，达25.6亿美元。

**Q: 哪些应用正在推动内源性大麻素治疗市场的增长？**
A: 疼痛管理在2024年的估值为25.6亿美元，是推动市场增长的关键应用。

**Q: 大麻素补充剂在市场规模方面与其他细分市场相比如何？**
A: 基于大麻素的补充剂在2024年的价值为24亿美元，显示出强大的市场存在。

**Q: 在内源性大麻素治疗市场中，最常见的给药途径有哪些？**
A: 口服给药在2024年的价值为19.2亿美元，目前是最普遍的给药途径。

**Q: 哪个最终用户细分市场预计将主导内源性大麻素治疗市场？**
A: 家庭护理部门在2024年的估值为29.3亿美元，预计将主导市场。

**Q: 在内源性大麻素治疗市场中，关键参与者是谁？**
A: 主要参与者包括GW制药公司、Canopy Growth Corporation和Tilray, Inc.

**Q: 未来几年基于大麻素的外用产品的预期增长趋势是什么？**
A: 基于大麻素的外用产品在2024年的价值为14.5亿美元，预计到2035年将经历显著增长。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/endocannabinoid-therapeutics-market-40270*